KUALA LUMPUR, Malaysia, July 28, 2025 /PRNewswire/ — Bossjob, Southeast Asia’s chat-based AI job platform, today announced its official launch in Malaysia, bringing job seekers and employers a faster, smarter, more human-centric way to connect. The new job platform in Malaysia aims to transform how Malaysians find work—especially among Gen Z and gig economy workers.

Why Malaysia, Why Now? 

Malaysia is in the middle of a digital shift, driven by its mobile-first, youth-dominated population. As demand for flexible, blue-collar, and entry-level jobs surges, Bossjob steps in with a bold promise: faster hiring, AI-powered matchmaking, and instant communication—right from your phone.

But this isn’t a pilot—it’s a proven formula. Bossjob has already helped over 100 million jobseekers globally, with local operations focused on serving the Philippines, Singapore, Indonesia and Japan. Since 2023, we’ve seen a 500% increase in monthly active users in the Philippines alone, while becoming the #1 downloaded chat-first job app in the country. Over 10 million messages have been exchanged between jobseekers and employers, with an average response time of under 10 minutes. Most users complete their job applications in less than 90 seconds.

Our AI-matching engine delivers real-time, relevant roles—83% of jobseekers receive a match within 24 hours, and 78% are hired within just 7 days of chatting. That’s hiring in under a week—without the waiting game.

What Makes Bossjob Different?

• Chat–first hiring – Message employers instantly, eliminating lengthy application forms and long wait times.
• AI-powered job matching – Our algorithms understand applicant skills, preferences, and chat behavior, delivering relevant job matches in real time.
• Simplified profile creation – No more juggling CV formats. Our streamlined profile process means users can apply with one tap.

“We are committed to making job searching more accessible and efficient for job seekers,” said Bernie Goh, Country Manager Malaysia of Bossjob. “Through this campaign, we aim to connect with job seekers on the go, reinforcing our commitment to simplifying the job search process and empowering job seekers with fast and direct access to employers.”

Bossjob is already helping businesses move at the speed of chat.

“Bossjob helped us connect quickly and meaningfully with Malaysia’s young talent during our KL launch. Unlike traditional platforms, their chat-first model let us engage candidates instantly—speed made all the difference,” said Chevelle Tham, HR Manager & Hiring Lead at Hvala.

Available Nationwide

Bossjob’s mobile app and web platform are now available nationwide. With job locations initially focused on Kuala Lumpur and Johor, jobseekers in Bossjob Malaysia can:

• Instantly connect with F&B, logistics, retail, and office employers.
• Discover AI-curated roles suited to their profile.
• Skip long registration processes; profile setup takes under two minutes.

“Bossjob isn’t just offering a new job search alternative in Malaysia—it’s equipping jobseekers with the tools and Gen AI technology to optimise their candidate profiles,” Goh added. “From fresh graduates to seasoned professionals, we believe every jobseeker deserves not only fast access to opportunities, but also the means to present their best self to employers.”

Vision for Southeast Asia

Bossjob’s Malaysia launch is part of its broader mission: to make job hunting instant, equitable, and accessible across the region. With 8,000+ active employers across Southeast Asia—including brands like Jollibee, Lazada, and Uniqlo—we’re already trusted by 60% of SMEs in the Philippines and 40% of Singapore’s fastest-growing startups. In Japan, we were the first chat-based platform to enter the gig market, achieving over 90% satisfaction in our pilot phase.

Get Started

Join over 2.5 million users across Southeast Asia who are transforming their job search with Bossjob. With AI-curated roles, real-time chat with employers, and hiring in under a week, it’s the fastest way to get hired in the region.

Bossjob has facilitated over 5 million job connections in the Philippines, Singapore, and Japan—making us Southeast Asia and Japan’s fastest-growing job-matching platform.

Bossjob’s AI-driven chat engine is redefining job search—delivering relevant jobs in real-time, not weeks.

Bossjob is now live in Malaysia. Download our app from the App Store or Google Play—or sign up online and start chatting. Your next job could be one message away.

About Bossjob

Bossjob is a chat-first, AI-powered job platform transforming hiring across Blue­-collar, gig, and Gen Z sectors. With over 1 million downloads and thousands of successful connections in SEA, Bossjob is on a mission to reinvent job search—one chat at a time.

Premium dermocosmetic brand specialising in sensitive skin launches from August 26th, bringing clinically-proven innovation to Australian skincare market

SYDNEY, July 28, 2025 /PRNewswire/ — AESTURA, Korea’s #1 dermatologist-recommended dermocosmetic brand for sensitive skin^[1], breaks new ground in the Australian skincare market with its exclusive launch at Sephora Australia stores and on Sephora.com.au, beginning August 26th, 2025. This strategic partnership with Sephora Australia answers the growing demand for advanced, science-backed solutions in the dermatologist skincare category.

AESTURA is more than just a skincare brand. It is the culmination of over 40 years of scientific research and dermatological expertise. AESTURA’s specialised sensitive skin solutions are trusted by dermatologists at Korea’s leading medical institutions. The brand has been ranked as the No. 1 cosmetic brand sold in skin clinics for 9 consecutive years^[2], and has widespread distribution, reaching 100% of tertiary general hospitals in South Korea^[3].

“We are thrilled to introduce AESTURA to our Australian beauty community,” says Sheila Dam, Brand General Manager at AESTURA. “Our products and formulas have been trusted by Korean dermatologists and sensitive-skin users alike for decades, and now, with this launch at Sephora Australia, we are excited to share these innovative sensitive-skin solutions to a wider audience.”

AESTURA’s innovative skincare harnesses patented Triple-Lipid Technology™, featuring one million ceramide capsules in every bottle engineered to mimic the skin’s natural structure and target the fundamental pillars of skin health: hydration, protection, and restoration.

The ATOBARRIER365 Collection: Hero Products for Sensitive Skin

At the heart of AESTURA’s breakthrough skincare is the ATOBARRIER365 Collection, featuring the viral sensation ATOBARRIER365 Cream. The hero product has become a phenomenon in Korea, with one cream sold every 7 seconds^[6] due to its proven ability to strengthen, protect and hydrate the skin.

The ATOBARRIER365 Cream features patented technology with one million capsules packed with ceramides in every bottle^[4]. These capsules stay on the skin for up to 18 hours^[5], delivering hydration while strengthening, repairing, and protecting the moisture barrier which can be weakened in sensitive skin.

“Sensitive skin often struggles with compromised skin barrier, making it more susceptible to dryness and irritation,” says Dr. Richard D. Granstein, an academic dermatologist and Chair of AESTURA’s Derma-Science Advisory Board. Additionally, according to Dr. Y. Claire Chang, board-certified dermatologist at UnionDerm and clinical instructor at Mount Sinai Hospital, “For those with sensitive skin, ceramides are crucial. It’s not just about any ceramides, though. Sensitive skin benefits most from specific ceramides that mimic those naturally found in the skin. AESTURA’s innovative capsule technology, used in the ATOBARRIER³⁶⁵ Cream, encapsulates these barrier-boosting ceramides, allowing for deeper penetration to help rebuild and strengthen the skin’s natural barrier. Results reported from a clinical trial of the ATOBARRIER365 Cream demonstrated significantly enhanced skin hydration and improved barrier function.”

The complete ATOBARRIER³⁶⁵ Collection includes products formulated to address specific skin concerns like dryness, irritation, and barrier damage while enhancing overall skin health. Each product is designed for daily use, providing a complete routine specifically developed for sensitive skin needs.

Exclusive Launch at Sephora Australia

The exclusive partnership with Sephora Australia underscores both brands’ commitment to offering premium, results-driven skincare solutions. Sephora’s reputation for curating the world’s most coveted beauty brands makes it the ideal retail partner for AESTURA’s Australian debut.

“Sephora Australia is excited to exclusively launch AESTURA, bringing our clients access to Korea’s most trusted dermocosmetic brand,” says Mark O’Keefe, Country Manager Sephora ANZ.

“Our clients value effective, results-driven skincare, and AESTURA delivers on this by offering cutting-edge solutions specifically designed for sensitive skin that support barrier health. We look forward to introducing AESTURA to our Sephora community and know that it will be a valuable addition to our assortment.”

Market Impact and Availability

The Australian launch comes at a time when consumer interest in K-beauty and dermocosmetic products continues to grow, with Australian consumers increasingly seeking scientifically-backed skincare solutions and prioritising genuine skin health over trend-driven routines. Australia’s harsh environmental factors – from intense UV exposure to dramatic seasonal transitions – demand skincare solutions of exceptional calibre.

AESTURA’s arrival fills a crucial gap in the market for dermatologist-recommended brand that combine Korean innovation with clinical credibility.

Starting August 26th, AESTURA products will be available at all Sephora Australia and New Zealand stores nationwide and through Sephora’s online platform, ensuring accessibility for customers across the country.

About AESTURA

AESTURA is Korea’s #1 dermatologist-recommended dermocosmetic brand, dedicated to developing scientifically-proven skincare solutions that bridge the gap between cosmetics and dermatological care. Founded on the principle of combining advanced research with gentle effectiveness, AESTURA has earned the trust of Korean dermatologists and consumers alike. The brand’s commitment to clinical excellence and innovation has made it a leader in the Korean beauty industry and a sought-after name in global skincare markets.

For more information about AESTURA, visit https://int.aestura.com

Collaboration focuses on advancing clinically validated armored CAR technologies into first-in-human trials in Singapore and accelerate translational research from bench-to-bedside

SINGAPORE and LEXINGTON, Mass., July 28, 2025 /PRNewswire/ — Elpis Biopharmaceuticals, a clinical-stage cell therapy company developing bispecific armored CAR-T therapies for solid tumors, today announced the signing of a Memorandum of Understanding (MOU) with the National Cancer Centre Singapore (NCCS). The partnership aims to support collaborative cell therapy research and clinical trials for the treatment of a variety of cancers, including colorectal, pancreatic and ovarian cancers. CAR-T cell therapy is a form of immunotherapy that is currently only approved for use to treat blood cancers, such as certain types of lymphomas and multiple myeloma.

Elpis Biopharmaceuticals and NCCS commemorate signing of memorandum of understanding to advance translational cell therapy research in Singapore

As part of the agreement, Elpis will contribute clinically validated technologies for cancer treatment, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies. These technologies are already being investigated in Elpis’ global clinical trials of EPC-002 and EPC-003, with the goal of expanding their translational relevance across multiple tumor types. Plans are also underway for Elpis to establish a laboratory space at NCCS and co-share its equipment to enable more integrated and efficient collaboration.

“This partnership reflects our commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and, hopefully saving patients’ lives,” said Yan Chen, MD, PhD, Founder and CEO of Elpis Biopharmaceuticals. “By combining Elpis’s proprietary technology with NCCS’s clinical expertise, we look forward to accelerating the delivery of these potential groundbreaking new cancer therapies to patients in Singapore and beyond.”

NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates.

“The potential of using cell therapies for solid tumors is still being explored, and this collaboration will enable us to evaluate promising new technologies in a clinical context to address current unmet needs and improve patient outcomes,” said Professor Lim Soon Thye, CEO of NCCS.

“This is a key collaboration with NCCS’ precision immunotherapy program. With our respective strengths and the shared goal of transforming clinical care through translational science, we look forward to offering clinical trials and developing novel cell therapies to better meet the needs of patients in Singapore and the region,” added Professor Daniel Tan, Head, Division of Clinical Trials and Epidemiological Sciences and Senior Consultant, NCCS.

The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis’s global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond. 

“The MOU represents an expansion of Elpis’s living drug strategy and a key step toward enabling broader clinical translation of our cutting-edge cell therapy technologies,” said Chee-Yong Lim, Co-Founder, Co-CEO & Chief Strategy Officer, Elpis Biopharmaceuticals. “Together, we are working to make living drugs a reality for patients with cancers that currently lack effective treatment options.”

About Elpis Biopharmaceuticals
Elpis Biopharmaceuticals is a clinical-stage biopharma company pioneering next-generation cell therapies for the treatment of solid tumors. The company is advancing a pipeline of first- and best-in-class bispecific armored CAR-T therapies designed to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor microenvironment. Its proprietary platforms—including a multi-mechanism armor technology, bispecific targeting antibodies, a cytokine cocktail-based cell manufacturing process, and a rapid mRNA display discovery engine—are integrated to deliver safer, more durable, and more effective therapeutic responses. Elpis’s lead programs include EPC-003 for glioblastoma and EPC-002 for a broad range of solid tumors. Elpis Biopharmaceuticals is headquartered in Singapore and Boston, MA. For more information, visit www.elpisbiopharmaceuticals.com. 

Contact
Tiberend Strategic Advisors, Inc.
Jonathan Nugent (investors)
+1-205-566-3026
jnugent@tiberend.com

Eric Reiss (media)
ereiss@tiberend.com

HONG KONG, July 27, 2025 /PRNewswire/ — KouShiCare, a leading innovator in healthcare technology, is proud to announce a groundbreaking advancement in the treatment of dry eye disease. The company’s latest device harnesses the power of DWV™ Low-Level Laser Therapy (LLLT) technology, marking a significant step forward in light-based ocular care.

Approximately 344 million people worldwide suffer from dry eye disease. This condition causes discomfort, blurred vision, and a significant decline in quality of life. Traditional treatments, like eye drops and medications, often offer only temporary relief and may not effectively address underlying gland dysfunction.

KouShiCare’s latest innovation, the LuminEyes Light Therapy Device, utilizes LLLT (Low-Level Light Therapy) and DWV™ LLLT (Dual-Wavelength Low-Level Light Therapy) technology to promote cellular metabolism and tissue repair. The LLLT uses low-power LEDs, no more than 100mW/cm², to deliver precise red or near-infrared light to biological tissues while preventing thermal damage. Additionally, by irradiating the eyelids and Meibomian glands with LEDs at 600nm (visible red light) ～ 900nm (near-infrared light), DWV™ LLLT stimulates ocular metabolism through PBM (photobiomodulation), harnessing biological regulatory effects to enhance eye health.

Numerous research and clinical studies have demonstrated that Red Light Therapy effectively softens blocked Meibomian gland lipids, improves the tear film’s lipid layer, alleviates dryness and the sensation of a foreign body, and enhances tear film stability. Compared to traditional treatments, it delivers more significant results while offering greater convenience and comfort.

KouShiCare’s commitment to innovation extends to user experience. The LuminEyes device is designed for ease of use, allowing patients to perform treatments comfortably at home. Key features include:

• 360-degree full coverage illumination ensuring uniform treatment
• Safe, non-invasive operation with no discomfort or downtime
• Integrated voice prompts and soothing background music to enhance the user experience
• Auto shut-off function and thermal management for added safety and energy efficiency

The LuminEyes Light Therapy Device is now available exclusively through the KouShiCare online store, offering a limited-time introductory discount of 15%. Patients seeking an effective, safe, and user-friendly solution to dry eye symptoms are encouraged to explore the benefits of this innovative device.

Visit us online for more details and purchase: https://koushicare.com/products/koushicare-lumineyes-light-therapy-mask

SHANGHAI, July 27, 2025 /PRNewswire/ — A news report from english.shanghai.gov.cn

No plane ticket required. New Yorkers left Manhattan behind on July 26 to immerse themselves in the sights, sounds and flavors of Shanghai at the Lincoln Center, which marked Shanghai Day as part of its fourth annual Summer for the City event.

Over the course of more than 10 programs, organized by the Lincoln Center and the Center for China Shanghai International Arts Festival, the local audiences experienced a multifaceted portrait of Shanghai’s contemporary culture where traditional aesthetics intersect with modern innovation.

Visitors from diverse backgrounds were treated to a wide array of attractions including a Shanghai artisan market with handmade crafts and interactive demonstrations, and a fantastic screening of the animation classic The Monkey King: Uproar in Heaven.

“It’s July and it’s hot; and in July in Shanghai, it’s really hot, so you get a true sense of both Shanghai culture and Shanghai weather,” Bill Einreinhofer, a three-time Emmy Award-winning filmmaker, who has also made documentaries about Shanghai, told China Daily at the event.

The day saw a big concert inspired by the popular video game Arknights, which showcased Shanghai’s fusion of heritage and contemporary digital culture.

Andrew Cap, a content creator who has studied and lived in Shanghai, drew parallels between the two cities.

“I think there’s a lot of similarity between New York and Shanghai — the multiculturalism, the international feel,” he said, noting that Shanghai, with its relatable vibe and history, is a great first step for the people of New York to better understand China.

“There are parts of it (Shanghai) that feel like Europe, there are parts of it that feel very international, very modern. I think it’s a great place to go to experience China for the first time,” Cap added.

As part of the cultural program, the Shanghai Grand Theatre presented the dance drama Lady White Snake. The production re­imagined a 1000-year-old Chinese legend through the contemporary lens of transformation, identity and self-liberation.

Zhang Xiaoding, general manager of the Shanghai Grand Theatre, a key platform for promoting Shanghai’s cultural presence on the global stage, called bringing the production to the festival a significant step.

“In the past, we’ve had deep collaborations with many artistic groups and artists from Europe and the United States, but Lady White Snake marks our first time presenting an original work based on a traditional Chinese story to international audiences. Through this contemporary interpretation, we hope to showcase the creative direction of Chinese performing arts,” Zhang said.

Acclaimed ballerina Tan Yuanyuan, who is also the artistic director of Lady White Snake and former principal dancer of San Francisco Ballet, said it was her privilege to work on this production and bring it to new audiences. “For me, dancing is a bridge to a lot of places. Dance brings joy to people,” she added.

The members of the cast all boast strong international backgrounds. Liu Sirui, who plays White Snake, is principal dancer with Cincinnati Ballet, while Sun Jiayong, who plays Xu Xian, is a former principal dancer of Bejart Ballet Lausanne in Switzerland.

In addition to watching the cultural performances, the audiences engaged in a variety of interactive activities throughout the day, such as silk brocade weaving, calligraphy and seal carving — all of which highlighted traditional Chinese craftsmanship and local Shanghai culture.

Saundra Barnes, a professor who taught at Sun Yat-sen University in Guangzhou, Guangdong province, four decades ago, was clear about what makes Shanghai truly special. It’s the warmth of the people, the culture and the incredible food, she said.